Lucia Scarabel
15 Papers
29 Citations
Lucia Scarabel is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Lucia Scarabel,Francesca Perrone,Marica Garziera,Rossella Farra,Mario Grassi,Francesco Musiani,Concetta Russo Spena,Barbara Salis,Lucia De Stefano,Giuseppe Toffoli,Flavio Rizzolio,Federica Tonon,Michela Abrami,Gianluca Chiarappa,Gabriele Pozzato,Giancarlo Forte,Gabriele Grassi,Barbara Dapas +17 more
TL;DR: Despite the existing difficulties in siRNA delivery for HCC, the increasing scientific attention and breakthrough studies in this field is facilitating the design of novel and efficient technical solutions that may soon find practical applications.
27
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
TL;DR: Wang et al. as discussed by the authors summarized the ongoing clinical trials using pharmacological strategies, including vaccines, as prophylaxis to avoid SARS-CoV-2 infection or limit its transmission, and as early treatment of COVID-19.
21
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
TL;DR: The interaction between HLA-G polymorphs and CPT-11 was explored by means of computational modelling, confirming the hypothesis that C PT-11 could actually target the peptide binding cleft of the most common HLA.
HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
Marica Garziera,Saverio Virdone,Elena De Mattia,Lucia Scarabel,Erika Cecchin,Jerry Polesel,Mario D'Andrea,Nicoletta Pella,Angela Buonadonna,Adolfo Favaretto,Giuseppe Toffoli +10 more
TL;DR: This exploratory study identified new HLA-G 3′UTR polymorphisms/haplotypes as potential predictive markers of G3-4 toxicities in CRC.
14
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Alessia Bignucolo,Elena De Mattia,Rossana Roncato,E. Peruzzi,Lucia Scarabel,Maria Lydia D'andrea,Franca Sartor,Giulia Toffoli,Erika Cecchin +8 more
TL;DR: In this article , the authors describe the evolution of DPYD diagnostic activity at the National Cancer Institute, CRO-Aviano (Italy) over the last 10 years as a case example of a successful introduction of pharmacogenetic testing in clinical practice.